NCT05344443View on ClinicalTrials.gov

Lemborexant Shift Work Treatment Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

October 30, 2024

Study Completion Date

June 30, 2025

Conditions
Shift-Work Related Sleep Disturbance
Interventions
DRUG

Lemborexant

A dual orexin antagonist

DRUG

Placebo

A placebo that looks and tastes like Lemborexant tablets

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT05344443 - Lemborexant Shift Work Treatment Study | Biotech Hunter | Biotech Hunter